Stephens Consulting’s BioNTech BNTX Stock Holding History

Stephens Consulting’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500	Closed	-$49.3K	–	486
2025 Q3	$49.3K	Hold	500	–	–	0.02%	141
2025 Q2	$53.2K	Hold	500	–	–	0.01%	190
2025 Q1	$45.5K	Hold	500	–	–	0.01%	197
2024 Q4	$57K	Hold	500	–	–	0.01%	178
2024 Q3	$59.4K	Hold	500	–	–	0.02%	178
2024 Q2	$40.2K	Hold	500	–	–	0.01%	201
2024 Q1	$46.1K	Hold	500	–	–	0.01%	184
2023 Q4	$52.8K	Hold	500	–	–	0.02%	172
2023 Q3	$54.3K	Hold	500	–	–	0.02%	158
2023 Q2	$54K	Hold	500	–	–	0.02%	157
2023 Q1	$62.3K	Hold	500	–	–	0.04%	150
2022 Q4	$75.1K	Hold	500	–	–	0.05%	130
2022 Q3	$67.4K	Hold	500	–	–	0.06%	143
2022 Q2	$74.5K	Hold	500	–	–	0.06%	133
2022 Q1	$85.3K	Sell	500 -500	-50%	-$84K	0.07%	143
2021 Q4	$258K	Buy	+1,000	New	+$274K	0.21%	80

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stephens Consulting's BNTX Position: Q4 2025 in Review

Stephens Consulting sold out of BioNTech (BNTX) in Q4 2025, closing a stake of 500 shares — an estimated $49.3K sold.

Stephens Consulting first reported a position in BNTX in Q4 2021 and held it in 16 quarters. The position peaked at $258K in Q4 2021. 284 funds tracked by Wall St. Rank hold BNTX as of Q4 2025.

Stephens Consulting reported no remaining BioNTech position as of Q4 2025 after selling out during the quarter.
Stephens Consulting sold 500 BioNTech shares in Q4 2025, an estimated $49.3K.
Stephens Consulting first reported a position in BioNTech in Q4 2021 and held it in 16 quarters.
Stephens Consulting's BioNTech position peaked at $258K in Q4 2021.
284 funds tracked by Wall St. Rank held BioNTech as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.